<!--
title: SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study
description: doi: https://doi.org/10.1136/bmj-2021-068665 
published: true
date: 2022-01-13T11:40:47.454Z
tags: #vaccine, #bnt162b2, #sarscov2, #risk, #pfizer, #side, #effects, #myocarditis, #study, #vaccination, #myopericarditis, #cohort, #increased
editor: ckeditor
dateCreated: 2022-01-13T11:40:44.995Z
-->

<p><strong>Research</strong></p>
<h1><strong>SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study</strong></h1>
<p><i>BMJ</i> 2021; 375 doi: <a href="https://doi.org/10.1136/bmj-2021-068665">https://doi.org/10.1136/bmj-2021-068665</a> (Published 16 December 2021)Cite this as: BMJ 2021;375:e068665</p>
<h2><a href="https://www.bmj.com/content/375/bmj.n3090">Linked Editorial</a></h2>
<p><a href="https://www.bmj.com/content/375/bmj.n3090">Myocarditis after vaccination against covid-19</a></p>
<ul>
  <li><a href="https://www.bmj.com/content/375/bmj-2021-068665">Article</a></li>
  <li><a href="https://www.bmj.com/content/375/bmj-2021-068665/related">Related content</a></li>
  <li><a href="https://www.bmj.com/content/375/bmj-2021-068665/article-info">Metrics</a></li>
  <li><a href="https://www.bmj.com/content/375/bmj-2021-068665/rapid-responses">Responses</a></li>
  <li><a href="https://www.bmj.com/content/375/bmj-2021-068665/peer-review">Peer review</a></li>
</ul>
<ol>
  <li><i>Anders Husby, physician</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-1"><i><strong>1 </strong></i></a><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-2"><i><strong>2</strong></i></a><i>,</i></li>
</ol>
<p>&nbsp;</p>
<ol>
  <li><i>Jørgen Vinsløv Hansen, statistician</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-2"><i><strong>2</strong></i></a><i>,</i></li>
  <li><i>Emil Fosbøl, consultant</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-3"><i><strong>3</strong></i></a><i>,</i></li>
  <li><i>Emilia Myrup Thiesson, statistician</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-2"><i><strong>2</strong></i></a><i>,</i></li>
  <li><i>Morten Madsen, statistician</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-4"><i><strong>4</strong></i></a><i>,</i></li>
  <li><i>Reimar W Thomsen, associate professor</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-4"><i><strong>4</strong></i></a><i>,</i></li>
  <li><i>Henrik T Sørensen, professor</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-4"><i><strong>4</strong></i></a><i>,</i></li>
  <li><i>Morten Andersen, professor</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-5"><i><strong>5</strong></i></a><i>,</i></li>
  <li><i>Jan Wohlfahrt, chief statistician</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-2"><i><strong>2</strong></i></a><i>,</i></li>
  <li><i>Gunnar Gislason, professor</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-6"><i><strong>6 </strong></i></a><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-7"><i><strong>7 </strong></i></a><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-8"><i><strong>8</strong></i></a><i>,</i></li>
  <li><i>Christian Torp-Pedersen, professor</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-9"><i><strong>9 </strong></i></a><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-10"><i><strong>10 </strong></i></a><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-11"><i><strong>11</strong></i></a><i>,</i></li>
  <li><i>Lars Køber, professor</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-3"><i><strong>3</strong></i></a><i>,</i></li>
  <li><i>Anders Hviid, professor</i><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-2"><i><strong>2 </strong></i></a><a href="https://www.bmj.com/content/375/bmj-2021-068665#aff-5"><i><strong>5</strong></i></a></li>
  <li>Correspondence to: A Husby <a href="mailto:andh@ssi.dk"><u>andh@ssi.dk</u></a> (or <a href="https://twitter.com/a_husby">@a_husby</a> on Twitter)</li>
</ol>
<ul>
  <li><strong>Accepted </strong>30 November 2021</li>
</ul>
<h2>Abstract</h2>
<p><strong>Objective</strong> To investigate the association between SARS-CoV-2 vaccination and myocarditis or myopericarditis.</p>
<p><strong>Design</strong> Population based cohort study.</p>
<p><strong>Setting</strong> Denmark.</p>
<p><strong>Participants</strong> 4 931 775 individuals aged 12 years or older, followed from 1 October 2020 to 5 October 2021.</p>
<p><strong>Main outcome measures</strong> The primary outcome, myocarditis or myopericarditis, was defined as a combination of a hospital diagnosis of myocarditis or pericarditis, increased troponin levels, and a hospital stay lasting more than 24 hours. Follow-up time before vaccination was compared with follow-up time 0-28 days from the day of vaccination for both first and second doses, using Cox proportional hazards regression with age as an underlying timescale to estimate hazard ratios adjusted for sex, comorbidities, and other potential confounders.</p>
<p><strong>Results</strong> During follow-up, 269 participants developed myocarditis or myopericarditis, of whom 108 (40%) were 12-39 years old and 196 (73%) were male. Of 3 482 295 individuals vaccinated with BNT162b2 (Pfizer-BioNTech), 48 developed myocarditis or myopericarditis within 28 days from the vaccination date compared with unvaccinated individuals (adjusted hazard ratio 1.34 (95% confidence interval 0.90 to 2.00); absolute rate 1.4 per 100 000 vaccinated individuals within 28 days of vaccination (95% confidence interval 1.0 to 1.8)). Adjusted hazard ratios among female participants only and male participants only were 3.73 (1.82 to 7.65) and 0.82 (0.50 to 1.34), respectively, with corresponding absolute rates of 1.3 (0.8 to 1.9) and 1.5 (1.0 to 2.2) per 100 000 vaccinated individuals within 28 days of vaccination, respectively. The adjusted hazard ratio among 12-39 year olds was 1.48 (0.74 to 2.98) and the absolute rate was 1.6 (1.0 to 2.6) per 100 000 vaccinated individuals within 28 days of vaccination. Among 498 814 individuals vaccinated with mRNA-1273 (Moderna), 21 developed myocarditis or myopericarditis within 28 days from vaccination date (adjusted hazard ratio 3.92 (2.30 to 6.68); absolute rate 4.2 per 100 000 vaccinated individuals within 28 days of vaccination (2.6 to 6.4)). Adjusted hazard ratios among women only and men only were 6.33 (2.11 to 18.96) and 3.22 (1.75 to 5.93), respectively, with corresponding absolute rates of 2.0 (0.7 to 4.8) and 6.3 (3.6 to 10.2) per 100 000 vaccinated individuals within 28 days of vaccination, respectively. The adjusted hazard ratio among 12-39 year olds was 5.24 (2.47 to 11.12) and the absolute rate was 5.7 (3.3 to 9.3) per 100 000 vaccinated individuals within 28 days of vaccination.</p>
<p><strong>Conclusions</strong> Vaccination with mRNA-1273 was associated with a significantly increased risk of myocarditis or myopericarditis in the Danish population, primarily driven by an increased risk among individuals aged 12-39 years, while BNT162b2 vaccination was only associated with a significantly increased risk among women. However, the absolute rate of myocarditis or myopericarditis after SARS-CoV-2 mRNA vaccination was low, even in younger age groups. The benefits of SARS-CoV-2 mRNA vaccination should be taken into account when interpreting these findings. Larger multinational studies are needed to further investigate the risks of myocarditis or myopericarditis after vaccination within smaller subgroups.</p>
<p>&nbsp;</p>
<p>Source: https://www.bmj.com/content/375/bmj-2021-068665</p>
